Literature DB >> 1394041

Microinvasive carcinoma of the cervix.

B U Sevin1, M Nadji, H E Averette, S Hilsenbeck, D Smith, B Lampe.   

Abstract

BACKGROUND: Microinvasive carcinoma of the cervix (MIC) has been poorly defined in the past and is still a focus of persistent controversy. In 1985, the International Federation of Gynecology and Obstetrics (FIGO) defined Stage IA as "preclinical invasive carcinoma, diagnosed by microscopy only," subdividing it into Stage IA1 or "minimal microscopic stromal invasion," and Stage IA2 or "tumor with invasive component 5 mm or less in depth taken from the base of the epithelium and 7 mm or less in horizontal spread." In 1974, the Society of Gynecologic Oncologists (SGO) defined MIC as any lesion with a depth of invasion of 3 mm or less from the base of the epithelium, without lymphatic or vascular space invasion.
METHODS: To assess the risk of lymph node metastasis and treatment failures, pathologic material and clinical data on 370 patients with Stage I carcinoma of the cervix, who were treated by radical hysterectomy and pelvic-aortic node dissection, were reviewed. Histopathologic analysis of tumors was based on a uniform format, including measurement of the maximum depth of invasion, the width and length of the horizontal tumor spread, invasive growth pattern, cell type, tumor grade, and lymphatic or vascular space involvement.
RESULTS: Of the 370 patients, 110 had a depth of invasion of 5 mm or less. Of these, 54 patients fulfilled the SGO definition of MIC; 42, the new FIGO Stage IA2 definition; and 27, both definitions. None of the patients with MIC, as defined by either the SGO or the new FIGO Stage IA2, had lymph node metastases or tumor recurrence. These data support the conclusion that MIC, defined by either the SGO or FIGO definitions, have a low risk for lymph node metastasis or recurrent carcinoma. A review of the literature indicated a recurrence rate for Stage IA2 of 4.2%. In addition to depth of invasion, lymph vascular space invasion is a better predictor of lymph node metastasis and recurrence than the surface dimension.
CONCLUSIONS: The authors recommend adoption of the SGO definition of MIC. Patients with a depth of invasion of 3 mm or less without lymph vascular space invasion safely can be treated conservatively.

Entities:  

Mesh:

Year:  1992        PMID: 1394041     DOI: 10.1002/1097-0142(19921015)70:8<2121::aid-cncr2820700819>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix.

Authors:  Andres A Roma; Oluwole Fadare
Journal:  Virchows Arch       Date:  2018-02-05       Impact factor: 4.064

2.  New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.

Authors:  Andres A Roma; Toni-Ann Mistretta; Andrea Diaz De Vivar; Kay J Park; Isabel Alvarado-Cabrero; Golnar Rasty; Jose G Chanona-Vilchis; Yoshiki Mikami; Sung R Hong; Norihiro Teramoto; Rouba Ali-Fehmi; Denise Barbuto; Joanne K L Rutgers; Elvio G Silva
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

3.  Pattern classification of endocervical adenocarcinoma: reproducibility and review of criteria.

Authors:  Joanne K L Rutgers; Andres A Roma; Kay J Park; Richard J Zaino; Abbey Johnson; Isabel Alvarado; Dean Daya; Golnar Rasty; Teri A Longacre; Brigitte M Ronnett; Elvio G Silva
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

4.  Radical hysterectomy with pelvic lymphadenectomy: indications, technique, and complications.

Authors:  Rachel A Ware; John R van Nagell
Journal:  Obstet Gynecol Int       Date:  2010-09-01

Review 5.  Barriers and Challenges to Treatment Alternatives for Early-Stage Cervical Cancer in Lower-Resource Settings.

Authors:  Emily S Wu; Jose Jeronimo; Sarah Feldman
Journal:  J Glob Oncol       Date:  2017-05-11

6.  Radical Trachelectomy for the Treatment of Early-Stage Cervical Cancer: A Systematic Review.

Authors:  Evan S Smith; Ashley S Moon; Robin O'Hanlon; Mario M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Jennifer J Mueller
Journal:  Obstet Gynecol       Date:  2020-09       Impact factor: 7.623

7.  Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.

Authors:  Naoto Sato; Yasushi Saga; Ryosuke Uchibori; Tomonori Tsukahara; Masashi Urabe; Akihiro Kume; Hiroyuki Fujiwara; Mitsuaki Suzuki; Keiya Ozawa; Hiroaki Mizukami
Journal:  Int J Oncol       Date:  2018-01-15       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.